Genmab Reports 22% Revenue Growth as Phase 3 Results Strengthen Oncology Portfolio
Genmab reported a 22% revenue increase to $3.238 billion for the first nine months, driven by higher royalties and EPKINLY sales. Positive Phase 3 results for epcoritamab, Rina-S, and petosemtamab strengthened its oncology portfolio. Operating expenses rose 35% to $2.018 billion. Analysts rate GMAB stock as Hold with a $57.00 target, while Spark's AI rates it Neutral.
How this was made
The 30-second read
Why it matters
The earnings beat and trial successes provide a fresh catalyst that could drive short‑term price appreciation, while expense growth introduces a counterbalance.
Market read
First‑report earnings and pivotal trial data for a mid‑cap biotech, likely to influence trading decisions today.
What to watch
Potential regulatory hurdles for new indications and the reliance on royalty income from partner drugs.
Background
Genmab, a Danish biotech listed on Nasdaq (GMAB), released its Q3‑2026 earnings and disclosed Phase 3 trial outcomes for epcoritamab, Rina‑S, and petosemtamab.
Ticker impact
Genmab reported 22% revenue growth to $3.238 bn for the first nine months and disclosed positive Phase 3 trial results for multiple oncology candidates.
potential upside as investors price in the revenue beat and positive trial readouts
Earnings beat and pivotal trial data are primary catalysts that typically move the stock in the near term.
Market effects
Positive data may boost the broader biotech oncology sector as investors reassess late‑stage pipelines.
European biotech markets could see modest gains from the upbeat results.
Adds to the global narrative of strong biotech earnings in Q3 2026.
Counterpoint
Higher operating expenses and execution risk could limit upside; investors may wait for cash‑flow clarity.
Key entities
- companyGenmab A/S
Biotechnology firm focused on antibody‑based cancer therapies.
- productDARZALEX
Partner‑developed antibody therapy generating royalty revenue for Genmab.
